ALung completes pilot study of Hemolung RAS in COPD patients

ALung Technologies, Inc., a leading developer of innovative lung assist devices, presented an analysis of its recent clinical trial of the Hemolung Respiratory Assist System (RAS) in patients with acute exacerbation of chronic obstructive pulmonary disease (COPD). The data were presented during the session "Chronic and Acute Hypercapnic Failure - Management with low flow CO₂ devices" on Friday, June 15th at the 58th Annual Conference of the American Society of Artificial Internal Organs (ASAIO) in San Francisco.

“We are pleased to have completed our pilot study of the Hemolung RAS and to be progressing towards obtainment of the CE mark”

The presentation, entitled "Extracorporeal CO₂ Removal (ECCO₂R) for Preventing Intubation in Patients with Exacerbated COPD: Results of the Hemolung Pilot Study," by Dr. William Federspiel, Professor of Bioengineering at the University of Pittsburgh and Chairman of ALung's Scientific Advisory Board, provided data from a subset of seven patients with acute exacerbation of COPD who were failing non-invasive ventilation (NIV) and at a high risk of being intubated and placed on invasive mechanical ventilation (IMV). Patients in the study were provided ECCO₂R with the Hemolung RAS to remove retained carbon dioxide. The study was led by principal investigator Prof. Dr. Felix Herth of the Thoraxklinik and University Hospital, Heidelberg, Germany.

In his presentation, Dr. Federspiel highlighted the improvement in respiratory status seen in these patients with severe exacerbations in which the Hemolung RAS was applied. Arterial pCO₂ levels were reduced on average by 28% within 24 hours, leading to lessening dyspnea and improved clinical status. The device provided effective and stable CO₂ removal on the order of 75 to 95 mL/min or up to approximately 50% of metabolic production. No unexpected adverse events were observed. All patients were able to avoid intubation while treated with the Hemolung RAS.

COPD afflicts over 14 million Americans and leads to nearly 140,000 deaths annually, making it the third leading cause of death. Acute exacerbations are a serious complication of COPD in which patients suffer a sudden worsening of their symptoms. In severe cases, patients will develop acute respiratory failure and require invasive mechanical ventilatory support. "These patients that go on to be mechanically ventilated often have a very poor prognosis with survival ranging from 31% to 76%," said Dr. Nausherwan Burki, Professor of Medicine at the University of Connecticut Health Center and ALung's Medical Director. "The ability of the Hemolung RAS to help patients with severe acute exacerbation of COPD avoid intubation and invasive mechanical ventilation fills an important, unmet clinical need."

"We are pleased to have completed our pilot study of the Hemolung RAS and to be progressing towards obtainment of the CE mark," said Peter DeComo, ALung's Chairman and CEO. "There is tremendous clinical enthusiasm for the Hemolung RAS, and we're looking forward to introducing the product to key reference centers throughout Europe in the near future."